

34th BioCity Symposium

TRANSFORMING DRUG DEVELOPMENT FOR TOMORROW

28-29 August 2025 in Mauno Koivisto Centre, BioCity, Turku, Finland

THURSDAY, 28 AUGUST 2025

08.30 **Marjo Kaartinen**, Rector, University of Turku

Opening words and presentation of the Elias Tillandz prize

KEYNOTE LECTURE

09.00 Nathanael S. Gray, Stanford University, USA
 Molecular glues to induce cancer cell death
 09.30 Q&A

SESSION I – DRUG DISCOVERY TECHNOLOGIES

- 09.40 **Christian Heinis**, École Polytechnique Fédérale de Lausanne, Switzerland *Development of cyclic peptides for oral administration*
- 10.10 Q&A
- 10.20 Short talk 1 selected from abstracts
- 10.35 POSTER SESSION A with coffee and tea
- 11.35 **Francesca E. Morreale**, The Francis Crick Institute, UK *Hijacking protein degradation in bacteria*
- 12.05 Q&A
- 12.15 Short talk 2 and 3 selected from abstracts
- 12.45 LUNCH and exhibitions

SESSION II – DRUG DISCOVERY TECHNOLOGIES

- 14.00 Carmen Galan, University of Bristol, UK
 Sweet solutions to tackle antimicrobial resistance: Towards the development of new glycan-based diagnostic tools
- 14.30 Q&A
- 14.40 **Hélder A. Santos**, University Medical Center Groningen; University of Groningen, The Netherlands Polysaccharide-based nanoformulations for myocardium infarction therapy: RNA-applications for mending the broken hearts
- 15.10 Q&A
- 15.20 POSTER SESSION B with coffee and tea





16 20	Short talk 4	selected	from :	ahstracts
10.20	SHULL LAIK 4	selecteu	11 0111 6	สมรถ สนเร

- 16.35 **Teemu Junttila**, Genentech, Research Oncology, USA Synthetic immunity through T Cell bispecifics: overcoming barriers in solid tumor targeting
- 17.05 Q&A
- 17.15 First symposium day ends
- 19.00 Symposium dinner

FRIDAY, 29 AUGUST 2025

SESSION III - OVERCOMING VALLEY OF DEATH

- 09.00 **Richard Marais**, Oncodrug Ltd, UK
 Setting up a biotech company after 35 years in academia
- 09.30 Q&A
- 09.40 **Silvia Marsoni**, IFOM ETS The AIRC Institute of Molecular Oncology, Italy *Timing is everything: Can understanding tumor biology help overcome the drug development dead zone?*
- 10.10 Q&A
- 10.20 Short talk 5 selected from abstracts
- 10.35 POSTERS with coffee and tea
- 11.35 **Maarit Merla**, Finnish Drug Discovery Center Ltd, Finland

 Turning innovations into successful products with Finnish Drug Discovery Center
- 12.05 Q&A

SESSION IV - CLINICAL DRUG DEVELOPMENT

- 12.15 **Anniina Färkkilä**, University of Helsinki, Finland *Harnessing spatial biology for advancing precision medicine*
- 12.45 Q&A
- 12.55 LUNCH and exhibitions
- 14.15 Short talk 6 and 7 selected from abstracts
- 14.45 **Petri Bono**, Faron Pharmaceuticals, Finland *Targeting immunosuppression in cancer: Bexmarilimab phase 2 results*
- 15.15 Q&A
- 15.25 **David Leppert**, University Hospital Basel, Switzerland *Biomarkers in drug development: getting more for less*
- 15.55 Q&A
- 16.05 **Klaus Elenius**, BioCity Turku Scientific Director *Closing remarks*

